Does the patient with myelofibrosis feel better through pacritinib?

Share :
Published: 12 Jun 2015
Views: 2131
Rating:
Save
Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA

At a press conference at EHA 2015, Dr Mesa presented new data from the Phase 3 PERSIST-1 study which showed that pacritinib is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with myelofibrosis.

Read the news story for more.